Recent studies into retatrutide peptide highlight promising potential for treating obesity and type disease. The compound, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, looks to provide enhanced weight reduction and glycemic regulation versus existing medications. Ongo